TherapeuticsMD (NASDAQ:TXMD) and Plus Therapeutics (NASDAQ:PSTV) Head to Head Analysis

TherapeuticsMD (NASDAQ:TXMD) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation.

Institutional & Insider Ownership

30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by insiders. Comparatively, 2.5% of Plus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares TherapeuticsMD and Plus Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02 million	7.66	-$570,000.00	($0.01)	-200.00
Plus Therapeutics	$5.21 million	6.91	-$22.39 million	($31.00)	-0.17

TherapeuticsMD has higher earnings, but lower revenue than Plus Therapeutics. TherapeuticsMD is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

TherapeuticsMD has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, Plus Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for TherapeuticsMD and Plus Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1	0	0	0	1.00
Plus Therapeutics	1	2	4	0	2.43

Plus Therapeutics has a consensus price target of $58.00, suggesting a potential upside of 1,004.76%. Given Plus Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than TherapeuticsMD.

Profitability

This table compares TherapeuticsMD and Plus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
Plus Therapeutics	-429.43%	N/A	-92.28%

About TherapeuticsMD

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

About Plus Therapeutics

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.